Clinical Trial Update: Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating topical sirolimus 2% for patients with epidermolysis bullosa simplex.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Simplex
• Epidermolysis Bullosa Simplex Kobner
• Weber-cockayne Syndrome

Drugs mentioned

• Topical Sirolimus 2% (sirolimus)

Snippet

Sponsor: Premier Specialists, Australia | Conditions: Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner | Phase 2 | Status: UNKNOWN